Endocrine therapy (ET) is a standard treatment to target hormone receptor-positive (HR+) neoplastic growths in people with HR+ breast cancer, and is typically prescribed for five to ten consecutive years [1]. The gene discussed is NR4A1; the disease is breast carcinoma.